重组人脑利钠肽联合左西孟旦治疗脓毒症心力衰竭的效果观察

王斌; 蔡薛芳; 林乐清

doi:10.16766/j.cnki.issn.1674-4152.002357

重组人脑利钠肽联合左西孟旦治疗脓毒症心力衰竭的效果观察

doi: 10.16766/j.cnki.issn.1674-4152.002357

1.
杭州师范大学附属医院重症医学科，浙江杭州 310000
2.
杭州师范大学附属医院体检中心，浙江杭州 310000

基金项目:

浙江省医药卫生科技计划项目 2020KY217

详细信息

通讯作者:
林乐清，E-mail：690861687@qq.com

中图分类号: R631 R541.6
计量
- 文章访问数: 216
- HTML全文浏览量: 76
- PDF下载量: 6
- 被引次数: 0
出版历程
- 收稿日期: 2021-03-18
- 网络出版日期: 2022-08-13

Effect of recombinant human brain natriuretic peptide combined with levosimendan in patients with septic heart failure

1.
Department of Critical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang 310000, China

摘要

摘要: 目的探讨重组人脑利钠肽(recombinant human brain natriuretic peptide, rh-BNP)联合左西孟旦治疗脓毒症心力衰竭的疗效及安全性，分析其对患者外周血miR-132、miR-31水平的影响。方法选择2017年3月—2019年6月杭州师范大学附属医院收治的脓毒症并发心力衰竭患者117例，采用随机数字表法分为观察组(61例)和对照组(56例)，对照组采用左西孟旦治疗，观察组采用左西孟旦联合rh-BNP治疗。比较2组急性生理与慢性健康评分(acute physiology and chronic health evaluation Ⅱ, APACHEⅡ)、心功能指标[左室收缩末期内径(left ventricular end systolic diameter, LVESD)、左室舒张末期内径(left ventricular end diastolic diameter, LVEDD)、左室射血分数(left ventricular ejection fraction, LVEF)、左心室短轴缩短率(left ventricular fraction shortening, LVFS)]、心肌酶谱[乳酸脱氢酶(lactate dehydrogenase，LDH)、肌酸激酶(creatine kinase, CK)、肌酸激酶同工酶(creatine kinase-MB, CK-MB)]、外周血miR-132、miR-31及不良反应。结果治疗后，观察组APACHE Ⅱ评分[(14.62±1.74)分]低于对照组[(16.96±2.73)分，t=5.575，P＜0.05]；观察组LVEDD[(48.93±4.28)mm]、LVESD[(39.42±4.16)mm]、LVFS[(22.31±1.75)%]低于对照组[(52.18±3.95)mm、(42.28±3.74)mm、(24.97±1.89)%，t=4.257、3.898、7.905，均P＜0.05)]；治疗后，观察组血清LDH、CK、CK-MB低于对照组(均P＜0.05)。患者外周血miR-31相对表达量与LVEDD、LVESD、LDH、CK以及CK-MB呈正相关关系(均P＜0.05)。结论重组人脑利钠肽联合左西孟旦治疗脓毒症心力衰竭可有效改善临床症状、心功能，同时可改善患者外周血miR-132及miR-31表达水平。
- 重组人脑利钠肽 /
- 左西孟旦 /
- 脓毒症 /
- 心力衰竭 /
- 临床疗效 /
- 相关性
Abstract: Objective To explore and analyse the efficacy and safety of recombinant human brain natriuretic peptide (rh-BNP) combined with levosimendan in the treatment of septic heart failure, and analyse its effect on miR-132 and miR-31 levels in patients' peripheral blood. Methods A total of 117 patients with sepsis and heart failure who were admitted at the Affiliated Hospital of Hangzhou Normal University from March 2017 to June 2019 were selected. The random number table method was used to divide the observation group (61 cases) and the control group (56 cases). The control group was treated with levosimendan, and the observation group was treated with levosimendan combined with rh-BNP. The APACHE Ⅱ score, cardiac function indexes, myocardial enzyme spectrum, peripheral blood miR-132 and miR-31 and adverse reactions were compared between the two groups. Results After treatment, the APACHE Ⅱ score of the observation group[(14.62±1.74) points] was lower than that of the control group[(16.96±2.73) points, t=5.575, P < 0.05]. The LVEDD[(48.93±4.28) mm], LVESD[(39.42±4.16) mm] and LVFS[(22.31±1.75)%] of the observation group were lower than those of the control group[(52.18±3.95) mm, (42.28±3.74) mm, (24.97±1.89)%, respectively, t=4.257, 3.898, 7.905, all P < 0.05]. The serum LDH, CK and CK-MB levels in the observation group were lower than those in the control group (all P < 0.05). The relative expression of miR-31 in the peripheral blood of patients was positively correlated with LVEDD, LVESD, LDH, CK and CK-MB (all P < 0.05). Conclusion rh-BNP combined with levosimendan in the treatment of septic heart failure can effectively improve the clinical symptoms and cardiac function, and it can also improve the expression of miR-132 and miR-31 in the peripheral blood of patients.
- Recombinant human brain natriuretic peptide /
- Levosimendan /
- Sepsis /
- Heart failure /
- Clinical efficacy /
- Correlation

HTML全文

图 1 miR-132与心功能及心肌酶谱各指标的相关性分析

Figure 1. Correlation analysis of miR-132 with cardiac function and cardiac enzymes

下载: 全尺寸图片幻灯片

图 2 miR-31与心功能及心肌酶谱各指标的相关性分析

Figure 2. Correlation analysis of miR-31 with cardiac function and cardiac enzymes

下载: 全尺寸图片幻灯片

表 1 2组脓毒症并发心力衰竭患者临床资料比较

Table 1. Comparison of clinical data of two groups of patientswith sepsis complicated with heart failure

组别	例数	性别(例)		年龄(x±s, 岁)	心功能分级(例)
组别	例数	男性	女性	年龄(x±s, 岁)	Ⅲ	Ⅳ
观察组	61	36	25	65.61±8.32	42	19
对照组	56	31	25	64.11±7.21	36	20
统计量		0.160^a		1.032^b	0.274^a
P值		0.689		0.304	0.601
注：^a为χ²值，^b为t值。

下载: 导出CSV

表 2 2组脓毒症并发心力衰竭患者治疗前后APACHE Ⅱ评分比较(x±s, 分)

Table 2. Two groups of patients with sepsis complicatedwith heart failure before and after treatment comparisonof APACHE Ⅱ scores (x±s, points)

组别	例数	治疗前	治疗后
观察组	61	21.74±3.18	14.62±1.74^a
对照组	56	21.94±3.62	16.96±2.73^a
t值		0.318	5.575
P值		0.751	＜0.001
注：与同组治疗前比较，^aP＜0.05。

下载: 导出CSV

表 3 2组脓毒症并发心力衰竭患者治疗前后心功能指标比较(x±s)

Table 3. Comparison of cardiac function indexes in the two groups of patients with sepsis complicatedwith heart failure before and after treatment (x±s)

组别	例数	LVEDD(mm)		LVESD(mm)		LVEF(%)		LVFS(%)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	61	61.27±5.39	48.93±4.28^a	47.28±4.75	39.42±4.16^a	42.29±3.24	43.96±3.21^a	26.85±2.44	22.31±1.75^a
对照组	56	60.97±5.84	52.18±3.95^a	48.02±4.39	42.28±3.74^a	41.75±3.64	45.69±3.80^a	27.10±2.79	24.97±1.89^a
t值		0.289	4.257	0.873	3.898	0.849	3.500	0.517	7.905
P值		0.773	＜0.001	0.385	＜0.001	0.397	0.001	0.606	＜0.001
注：与同组治疗前比较，^aP＜0.05。

下载: 导出CSV

表 4 2组脓毒症并发心力衰竭患者治疗前后心肌酶谱变化(x±s, U/L)

Table 4. Changes of myocardial enzyme spectrum in patients with sepsis complicated with heart failure beforeand after treatment in two groups (x±s, U/L)

组别	例数	LDH		CK		CK-MB
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	61	277.64±56.38	167.28±31.65^a	209.74±23.17	160.87±16.48^a	61.27±6.19	21.31±3.42^a
对照组	56	272.61±49.70	203.46±44.27^a	207.64±28.46	185.62±22.02^a	61.75±6.85	30.46±4.22^a
t值		0.510	5.116	0.439	6.919	0.398	12.931
P值		0.611	＜0.001	0.661	＜0.001	0.691	＜0.001
注：与同组治疗前比较，^aP＜0.05。

下载: 导出CSV

表 5 2组脓毒症并发心力衰竭患者治疗前后外周血miR-132、miR-31相对表达量比较(x±s)

Table 5. Peripheral blood of two groups of patients with sepsiscomplicated with heart failure before and aftertreatment comparison of relative expressionlevels of miR-132 and miR-31 (x±s)

组别	例数	miR-132		miR-31
组别	例数	治疗前	治疗后	治疗前	治疗后
观察组	61	0.97±0.25	2.19±0.77^a	4.47±0.68	2.31±0.83^a
对照组	56	0.88±0.31	1.74±0.69^a	4.62±0.82	2.95±0.90^a
t值		1.735	3.318	1.080	4.001
P值		0.085	0.001	0.282	＜0.001
注：与同组治疗前比较，^aP＜0.05。

下载: 导出CSV

参考文献(20)

[1]	WYNN J L, POLIN R A. Progress in the management of neonatal sepsis: The importance of a consensus definition[J]. Pediatr Res, 2018, 83(1): 13-15. doi: 10.1038/pr.2017.224
[2]	吴淡森, 石松菁, 张瑞, 等. 脓毒症并多器官功能不全综合征患者的新型抑制性细胞因子IL-35表达及其临床意义[J]. 中华急诊医学杂志, 2019, 28(2): 175-180. WU D S, SHI S J, ZHANG R, et al. Expression and clinical significance of the novel inhibitory cytokine IL-35 in patients with sepsis and multiple organ dysfunction syndrome[J]. Chinese Journal of Emergency Medicine, 2019, 28(2): 175-180.
[3]	LEISMAN D E, DOERFLER M E, SCHNEIDER S M, et al. Predictors, prevalence, and outcomes of early crystalloid responsiveness among initially hypotensive patients with sepsis and septic shock[J]. Crit Care Med, 2018, 46(2): 189-198. doi: 10.1097/CCM.0000000000002834
[4]	张倩, 郭畅, 魏璐佳, 等. 左西孟旦对老年急性心肌梗死合并心力衰竭患者的临床疗效及安全性评价[J]. 中国医药, 2018, 13(4): 481-484. doi: 10.3760/cma.j.issn.1673-4777.2018.04.001 ZHANG Q, GUO C, WEI L J, et al. Therapeutic effect and safety of levosimendan on elderly patients with acute myocardial infarction complicated with heart failure[J]. China Medicine, 2018, 13(4): 481-484. doi: 10.3760/cma.j.issn.1673-4777.2018.04.001
[5]	张烜舜, 孙梦雯, 严光, 等. 冻干重组人脑利钠肽治疗老老年慢性心力衰竭患者的疗效观察[J]. 中华全科医学, 2018, 16(12): 1964-1966, 1999. doi: 10.16766/j.cnki.issn.1674-4152.000535 ZHANG J S, SUN M G, YAN G, et al. Clinical effect of lyophilized recombinant human brain natriuretic peptide on chronic congestive heart failure in the very old patients[J]. Chinese Journal of General Practice, 2018, 16(12): 1964-1966, 1999. doi: 10.16766/j.cnki.issn.1674-4152.000535
[6]	高戈, 冯喆, 常志刚, 等. 2012国际严重脓毒症及脓毒性休克诊疗指南[J]. 中华危重病急救医学, 2013, 25(8): 501-505. doi: 10.3760/cma.j.issn.2095-4352.2013.08.016 GAO G, FENG Z, CHANG Z G, et al. 2012 international diagnosis and treatment of severe sepsis and septic shock guideline[J]. Chinese Critical Care Medicine, 2013, 25(8): 501-505. doi: 10.3760/cma.j.issn.2095-4352.2013.08.016
[7]	田朝伟, 陈晓辉. 急性心力衰竭的诊治进展: 2016 ESC急慢性心力衰竭诊断和治疗指南[J]. 中华急诊医学杂志, 2016, 25(7): 854-857. doi: 10.3760/cma.j.issn.1671-0282.2016.07.002 TIAN C W, CHEN X H. Advances in diagnosis and treatment of acute heart failure: 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Chinese Journal of Emergency Medicine, 2016, 25(7): 854-857. doi: 10.3760/cma.j.issn.1671-0282.2016.07.002
[8]	支海君, 张萌, 崔晓雅, 等. 肾脏超声和血清胱抑素对急性肾损伤的预测价值: 在心力衰竭与脓毒症患者中的不同之处[J]. 中华危重病急救医学, 2019, 31(10): 1258-1263. doi: 10.3760/cma.j.issn.2095-4352.2019.10.015 ZHI H J, ZHANG M, CUI X Y, et al. Renal echography and cystatin C for prediction of acute kidney injury: Very different in patients with cardiac failure or sepsis[J]. Chinese Critical Care Medicine, 2019, 31(10): 1258-1263. doi: 10.3760/cma.j.issn.2095-4352.2019.10.015
[9]	BARNABY D P, FERNANDO S M, FERRICK K J, et al. Use of the low-frequency/high-frequency ratio of heart rate variability to predict short-term deterioration in emergency department patients with sepsis[J]. EMJ, 2018, 35(2): 96-102. doi: 10.1136/emermed-2017-206625
[10]	黄鑫, 孔红娇, 朱明娜, 等. 老年射血分数保留型心力衰竭患者不同性别相关因素分析及增强型体外反搏安全性观察[J]. 中华全科医学, 2021, 19(4): 564-567. doi: 10.16766/j.cnki.issn.1674-4152.001862 HUANG X, KONG H J, ZHU M G, et al. Analysis of different gender-related factors and observation of the safety of enhanced external counterpulsation in elderly patients with heart failure and preserved ejection fraction[J]. Chinese Journal of General Practice, 2021, 19(4): 564-567. doi: 10.16766/j.cnki.issn.1674-4152.001862
[11]	李瑞娜. 重组人脑利钠肽对急性心肌梗死并心源性休克疗效及预后分析[J]. 安徽医药, 2019, 23(4): 696-699. doi: 10.3969/j.issn.1009-6469.2019.04.016 LI R N. Efficacy and prognosis of recombinant human brain natriuretic peptide in acute myocardial infarction complicated with cardiogenic shock[J]. Anhui Medical and Pharmaceutical Journal, 2019, 23(4): 696-699. doi: 10.3969/j.issn.1009-6469.2019.04.016
[12]	宋添晶, 吴玉泉, 郦虹, 等. 重组人脑利钠肽治疗高龄心力衰竭患者的疗效观察及其对血清N端B型钠尿肽原水平的影响[J]. 中国基层医药, 2019, 26(9): 1070-1073. doi: 10.3760/cma.j.issn.1008-6706.2019.09.012 SONG T J, WU Y Q, LI H, et al. Effect of recombinant human brain natriuretic peptide on the cardiac function and serum N terminal pro-B-type natriuretic peptide level in elderly patients with heart failure[J]. Chinese Journal of Primary Medicine and Pharmacy, 2019, 26(9): 1070-1073. doi: 10.3760/cma.j.issn.1008-6706.2019.09.012
[13]	颜成敏, 葛赟, 周瑜, 等. 重组人脑利钠肽对急性失代偿性心功能衰竭合并急性肾功能损伤的临床疗效观察[J]. 中华急诊医学杂志, 2018, 27(9): 1041-1043. doi: 10.3760/cma.j.issn.1671-0282.2018.09.018 YAN C M, GE Y, ZHOU Y, et al. Clinical observation of recombinant human brain natriuretic peptide on acute decompensated heart failure complicated with acute renal impairment[J]. Chinese Journal of Emergency Medicine, 2018, 27(9): 1041-1043. doi: 10.3760/cma.j.issn.1671-0282.2018.09.018
[14]	王非, 张铮, 邱新成, 等. 低剂量重组人脑利钠肽治疗急性失代偿性心力衰竭合并肾功能不全的疗效观察[J]. 临床心血管病杂志, 2018, 34(6): 568-571. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB201806009.htm WANG F, ZHANG Z, QIU X C, et al. Therapeutic effect of low dose recombinant human brain natriuretic peptide on patients with acute decompensated heart failure and renal dysfunction[J]. Journal of Clinical Cardiology, 2018, 34(6): 568-571. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB201806009.htm
[15]	KIM Y S, KARISA N, JEON W Y, et al. High-level production of N-terminal pro-brain natriuretic peptide, as a calibrant of heart failure diagnosis, in Escherichia coli[J]. Appl Microbiol Biot, 2019, 103(12): 4779-4788. doi: 10.1007/s00253-019-09826-8
[16]	李亚昭, 魏新考, 于瑞双, 等. 重组人脑利钠肽联合左西孟旦治疗急性心力衰竭疗效观察[J]. 现代中西医结合杂志, 2019, 28(22): 2460-2463. doi: 10.3969/j.issn.1008-8849.2019.22.017 LI Y Z, WEI X K, YU R S, et al. Observation on the efficacy of recombinant human brain natriuretic peptide combined with levosimendan in the treatment of acute heart failure[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2019, 28(22): 2460-2463. doi: 10.3969/j.issn.1008-8849.2019.22.017
[17]	梁珊, 何亚州, 李丽娟, 等. miRNA-494与慢性心力衰竭心肌纤维化相关性的生物信息学分析[J]. 中国医药导报, 2019, 16(23): 7-11, 190. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201923002.htm LIANG S, HE Y Z, LI L J, et al. Bioinformatics analysis of the relationship between miRNA-494 and myocardial fibrosis in chronic heart failure[J]. China Medical Herald, 2019, 16(23): 7-11, 190. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201923002.htm
[18]	黄如彬, 王利莎, 丁力. 老年急性心力衰竭患者血清miR-181b表达与心功能指标及预后的关系[J]. 河北医药, 2019, 41(22): 3448-3450, 3454. doi: 10.3969/j.issn.1002-7386.2019.22.021 HUANG R B, WANG L S, DING L. The expression of miR-181b in elderly patients with acute heart failure and its relationship with cardiac function indexes and prognosis of patients[J]. Hebei Medical Journal, 2019, 41(22): 3448-3450, 3454. doi: 10.3969/j.issn.1002-7386.2019.22.021
[19]	田焕平, 吴海波, 刘惠良, 等. 急性心肌梗死并心力衰竭患者血清miR-132和miR-31水平及其临床诊断价值研究[J]. 重庆医学, 2019, 48(2): 248-251. doi: 10.3969/j.issn.1671-8348.2019.02.017 TIAN H P, WU H B, LIU H L, et al. Levels of serum miR-132 and miR-31 in heart failure patients with acute myocardial infarction and their value on clinical diagnostic[J]. Chongqing Medicine, 2019, 48(2): 248-251. doi: 10.3969/j.issn.1671-8348.2019.02.017
[20]	徐振宇, 杨立明, 李广平, 等. 慢性心力衰竭患者血清miR-133a、miR-133b水平与心功能和心肌重构的关系[J]. 山东医药, 2018, 58(4): 82-84. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYY201804028.htm XU Z Y, YANG L M, LI G P, et al. Relationship between serum miR-133A, miR-133b levels and cardiac function and remodeling in patients with chronic heart failure[J]. Shandong Medical Journal, 2018, 58(4): 82-84. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYY201804028.htm